PMID- 37741921
OWN - NLM
STAT- MEDLINE
DCOM- 20240311
LR  - 20240413
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Print)
IS  - 0301-1623 (Linking)
VI  - 56
IP  - 4
DP  - 2024 Apr
TI  - Repurposing fexofenadine as a promising candidate for diabetic kidney disease: 
      randomized clinical trial.
PG  - 1395-1402
LID - 10.1007/s11255-023-03804-w [doi]
AB  - PURPOSE: Diabetic kidney disease (DKD) is a devastating complication of diabetes 
      mellitus. Inflammation and histamine are potentially involved in the disease 
      progression. This study aimed to evaluate the role of fexofenadine in patients 
      with DKD. METHODS: From January 2020 to February 2022, out of 123 patients 
      screened for eligibility, 61 patients completed the study. Patients were 
      randomized into two groups, the fexofenadine group (n = 30): received ramipril 
      plus fexofenadine, and the control group (n = 31): received ramipril only for six 
      months. Changes in urinary albumin to creatinine ratio (UACR) and estimated 
      glomerular filtration rate (eGFR) were considered primary outcomes. Measurements 
      of urinary cyclophilin A, monocyte chemoattractant protein-1 (MCP-1), 
      8-hydroxy-2' deoxyguanosine (8-OHdG), and podocalyxin (PCX) were considered 
      secondary outcomes. The study was prospectively registered on clinicaltrial.gov 
      on January 13, 2020, with identification code NCT04224428. RESULTS: At the end of 
      the study, fexofenadine reduced UACR by 16% (95% CI, - 23.4% to - 9.3%) versus a 
      noticeable rise of 11% (95% CI, 4.1% to 17.8%) in UACR in the control group, 
      (p < 0.001). No significant difference in eGFR was revealed between the two 
      groups. However, the control group showed a significant decrease of - 3.5% (95% 
      CI, - 6.6% to - 0.3%) in eGFR, compared to its baseline value. This reduction was 
      not reported in the fexofenadine group. Fexofenadine use was associated with a 
      significant decline in MCP-1, 8-OHdG, and PCX compared to baseline values. 
      CONCLUSION: Fexofenadine is a possible promising adjuvant therapy in patients 
      with DKD. Further large-scale trials are needed to confirm our preliminary 
      results.
CI  - (c) 2023. The Author(s).
FAU - El-Fatatry, Basma Mahrous
AU  - El-Fatatry BM
AUID- ORCID: 0000-0002-7266-168X
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Al-Guiesh 
      Street, Tanta, 31527, Egypt. Basma.mahrous.clinical@gmail.com.
FAU - El-Haggar, Sahar Mohamed
AU  - El-Haggar SM
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Professor of Clinical 
      Pharmacy, Tanta University, Al-Geish Street, Tanta, Egypt.
FAU - Ibrahim, Osama Mohamed
AU  - Ibrahim OM
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Professor of Clinical 
      Pharmacy, Tanta University, Al-Geish Street, Tanta, Egypt.
FAU - Shalaby, Khaled Hamed
AU  - Shalaby KH
AD  - Department of Internal Medicine, Faculty of Medicine, Lecturer of Internal 
      Medicine, Tanta University, Al-Geish Street, Tanta, Egypt.
LA  - eng
SI  - ClinicalTrials.gov/NCT04224428
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20230923
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
RN  - E6582LOH6V (fexofenadine)
RN  - L35JN3I7SJ (Ramipril)
RN  - 7BA5G9Y06Q (Terfenadine)
SB  - IM
MH  - Humans
MH  - *Diabetic Nephropathies/etiology/complications
MH  - Ramipril/therapeutic use
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Kidney Function Tests
MH  - Glomerular Filtration Rate
MH  - Albuminuria/complications
MH  - Terfenadine/*analogs & derivatives
PMC - PMC10923951
OTO - NOTNLM
OT  - Albuminuria
OT  - Antihistamines
OT  - Diabetic kidney disease
OT  - Fexofenadine
COIS- The authors declare that they have no conflict of interest.
EDAT- 2023/09/24 00:42
MHDA- 2024/03/11 06:44
PMCR- 2023/09/23
CRDT- 2023/09/23 23:24
PHST- 2023/05/08 00:00 [received]
PHST- 2023/09/13 00:00 [accepted]
PHST- 2024/03/11 06:44 [medline]
PHST- 2023/09/24 00:42 [pubmed]
PHST- 2023/09/23 23:24 [entrez]
PHST- 2023/09/23 00:00 [pmc-release]
AID - 10.1007/s11255-023-03804-w [pii]
AID - 3804 [pii]
AID - 10.1007/s11255-023-03804-w [doi]
PST - ppublish
SO  - Int Urol Nephrol. 2024 Apr;56(4):1395-1402. doi: 10.1007/s11255-023-03804-w. Epub 
      2023 Sep 23.